# A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

> **NCT03875001** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dose group 1 - 50 mg BI 1358894
- **DRUG:** Dose group 2 - 100 mg BI 1358894
- **DRUG:** Dose group 3 - 200 mg BI 1358894

## Key facts

- **NCT ID:** NCT03875001
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2019-07-20
- **Final completion:** 2019-07-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875001, "A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03875001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*